Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Adicionar filtros








Intervalo de ano
1.
Rev. méd. Panamá ; 23(1): 14-16, Jan.-May 1998.
Artigo em Espanhol | LILACS | ID: lil-409828

RESUMO

It is presented the experience with 90 patients receiving Eritropoietin s.c. and oral iron who were in chronic haemodialysis. After basic laboratories, including iron kinetic, in all of them was stopped oral iron and started i.v. iron 60 mgs per week, but keeping the same eritropoietin doses. The results showed an increased haemoglobin level from 6.5 to 11 g/dl mean values and a decreased doses of eritropoietin between 25 to 50%. This represent an important elevation of haemoglobin levels at a significant low cost


Assuntos
Humanos , Adolescente , Adulto , Pessoa de Meia-Idade , Anemia Ferropriva , Eritropoetina/administração & dosagem , Eritropoetina/economia , Ferro/administração & dosagem , Hemoglobinas/análise , Hemoglobinas/economia , Insuficiência Renal Crônica/complicações , Custos e Análise de Custo , Doença Crônica , Injeções Intravenosas
2.
Rev. méd. Panamá ; 21(1/2): 55-59, Jan.-May 1996.
Artigo em Espanhol | LILACS | ID: lil-409923

RESUMO

Erythropoietin (EP) injected subcutaneously (SC) 2 or 3 times a week, respectively, or intravenously (IV) 3 times a week, increased the hemoglobin and the hematocrit of all the patients so treated. The total units of EP used was less when it was administered SC. EP once or twice a week, respectively, administered SC also increased the hemoglobin and hematocrit in each case, and the total amount of EP used was also less


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Anemia/terapia , Diálise Renal/efeitos adversos , Eritropoetina/administração & dosagem , Insuficiência Renal Crônica/sangue , Anemia/sangue , Anemia/etiologia , Esquema de Medicação , Hematócrito , Hemoglobina A , Insuficiência Renal Crônica/terapia , Injeções Intravenosas
3.
Rev. méd. Panamá ; 20(3): 116-123, Sept. 1995.
Artigo em Espanhol | LILACS | ID: lil-409931

RESUMO

The authors determined the frequency of genes and haplotypes of the HLA system in 965 panamanian men and women not related to each other, between 6 and 65 years of age. The HLA-A locus genes with the highest frequency (f) were A2, with f 0.1763; A24, f 0.1584; A30, f 0.1340; A23, f 0.1069; A3, f 0.0774. The other 20 genes each had less than 0.07. The genes with the highest frequency for locus HLA-B were B35, f 0.1946; B44, f 0.0904; B7, f 0.0774; B60 and B61, f 0.0582. For locus HLA-C, the most frequent genes were Cw3 with f 0.1549 and Cw4, f 0.1444. For locus HLA-DR, the most frequent genes were DR2 with f 0.1283; DR3, f 0.0620; DR7, f 0.0409. The most frequent haplotypes in the panamanian population were A2-B35 with f 0.0382; A3-B35, f 0.0191; A24-35, f 0.0287; A24-B61, f 0.0239; A29-B44, f 0.0287; A30-B42, f 0.0239; A23-B44, f 0.0191; A1-B8, f 0.0143. The authors conclude that the panamanian population exhibits a high degree of polymorphism for loci HLA-A, B and C, while for locu HLA-DR the frequency is the median when compared with that in caucasian, negro and oriental groups; and that, according to locus, predominant genes originating from these groups and found, corroborating the multiracial origen of the panamanian population


Assuntos
Humanos , Masculino , Feminino , Criança , Adolescente , Adulto , Pessoa de Meia-Idade , Antígenos HLA/genética , Frequência do Gene , Haplótipos , Antígenos HLA-A/genética , Antígenos HLA-B/genética , Panamá , Teste de Histocompatibilidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA